Biogen and Ionis Expand Collaboration to Develop Therapy Candidates for Alzheimer’s, Other Neurological Diseases

Biogen and Ionis Expand Collaboration to Develop Therapy Candidates for Alzheimer’s, Other Neurological Diseases
Biogen and Ionis Pharmaceuticals are expanding their strategic collaboration through a new 10-year agreement to develop novel RNA-targeted therapy candidates for a broad range of neurological diseases, including Alzheimer’s disease. This agreement builds on the collaboration that produced Spinraza (nusinersen), the first and only approved treatment for spinal muscular dystrophy (SMA), and capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ experience in developing ribonucleic acid (RNA) targeted therapies through its
Subscribe or to access all post and page content.